Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEden Research Regulatory News (EDEN)

Share Price Information for Eden Research (EDEN)

Share Price is delayed by 15 minutes
Get Live Data
3.00    0.00 (0.00%)
Bid:
2.90
Ask:
3.10
Spread: 0.20 (6.897%)
Market Cap: £24.10m
EDEN Live PriceLast checked at - London Stock Exchange

Intraday Eden Research Share Chart

Exercise of Options

8 May 2018 07:00

RNS Number : 2991N
Eden Research plc
08 May 2018
 

 

 

 

8 May 2018

 

Eden Research plc

 

("Eden" or "Company")

 

 

Exercise of Options

 

Director/PDMR Shareholding

 

Eden Research plc (AIM: EDEN), the AIM listed company that provides breakthrough natural microencapsulation technologies to the global agrochemicals, animal health and consumer products industries, announces it has issued 125,000 ordinary shares of 1 pence each in the Company ("Ordinary Shares") following the exercise of 125,000 options at 10.4 pence per share by the Company's Chief Financial Officer, Alex Abrey, under the Company's share option scheme.

 

Application has been made for the new Ordinary Shares to be admitted to trading on AIM, which is expected to take place on 14 May 2018. The new Ordinary Shares will rank, pari passu, with the existing Ordinary Shares in issue.

 

Following the transaction outlined above Mr Abrey's interest in the share capital of the Company has increased to a total of 1,163,160 Ordinary Shares representing 0.56 per cent. of the Company's issued share capital enlarged pursuant to the exercise of options. 

 

Total Voting Rights

Following the issue of the new Ordinary Shares, the Company will have 207,189,337 ordinary shares of 1 pence each in issue. No Ordinary Shares are held in treasury. The figure of 207,189,337 may be used by the Company's shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

 

 

 

 

 

 

 

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further details of the PDMR dealings set out above.

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Mr Alex Abrey

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chief Financial Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Eden Research plc

 

b)

 

LEI

 

 

213800ZWTYTVQQSM3J85

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary shares of 1 pence each in the Company ("Ordinary Shares")

 

GB0001646941

 

b)

 

Nature of the transaction

 

Exercise of Options over Ordinary Shares

 

 

 

 

 

c)

 

 

 

 

Price(s) and volume(s)

 

 

 

 

Exercise Price(s)

 

Volume(s)

 

10.4 pence per share

 

125,000 Ordinary Shares

 

 

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

 

 

 

N/A (single transaction)

 

e)

 

Date of the transaction

 

07/05/2018

f)

 

Place of the transaction

 

 

Outside of a trading venue.

 

 

 

For further information contact:

Eden Research plc

www.edenresearch.com

Sean Smith

Alex Abrey

01285 359 555

Shore Capital (Nomad)

020 7408 4090

Stephane Auton / Patrick Castle

Powerscourt (Financial PR)

020 7250 1446

Nick Dibden

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCGUGDUCDGBGII
Date   Source Headline
27th May 20267:00 amRNSDirectorate change
28th Apr 20267:00 amRNSTrading Update
16th Apr 20262:59 pmRNSHolding(s) in Company
14th Apr 20264:30 pmRNSHolding(s) in Company
14th Apr 20263:31 pmRNSHolding(s) in Company
13th Apr 202611:31 amRNSHolding(s) in Company
10th Apr 20267:00 amRNSCompletion of Conditional Placing and TVR
8th Apr 202612:10 pmRNSSatisfaction of Conditions of Conditional Placing
2nd Apr 20267:00 amRNSThymolflex EPA approval
19th Feb 20263:59 pmRNSHolding(s) in Company
19th Feb 20261:29 pmRNSHolding(s) in Company
18th Feb 20269:40 amRNSResult of General Meeting and Total Voting Rights
5th Feb 20262:50 pmRNSResult of Retail Offer
2nd Feb 20261:01 pmRNSLaunch of Retail Offer
2nd Feb 202612:57 pmRNSProposed Placing and Subscription
9th Jan 20267:00 amRNSNovellus+ Regulatory Authorisation in Chile
7th Jan 20267:00 amRNSMevalone Label Extension in France
18th Dec 20257:00 amRNSAppointment of Syngenta as Distribution Partner
20th Nov 20257:00 amRNS3LOGY Label Extension in Italy
17th Nov 20257:00 amRNSEcovelex 2025 Approval in Italy
17th Sep 20259:45 amRNSDirector/PDMR Shareholdings
17th Sep 20258:36 amRNSDirector/PDMR Shareholdings
17th Sep 20257:00 amRNSHalf Yearly Report
15th Sep 20257:00 amRNSNotice of Results
18th Jun 20251:40 pmRNSResult of AGM
18th Jun 20257:00 amRNSAGM Statement
16th Jun 20257:00 amRNSEcovelex Partnership with Royal Holloway
27th May 20255:22 pmRNSNotice of AGM
13th May 20257:00 amRNSMevalone Approval in California - Powdery Mildew
9th May 20257:00 amRNS-RInvestor Presentation via Investor Meet Company
6th May 202512:08 pmRNSHolding(s) in Company
6th May 20257:00 amRNSPreliminary results for the year ended 31 Dec 2024
10th Apr 20257:00 amRNSThymol Supply Agreement For Bee Health
1st Apr 202510:08 amRNSDirector/PDMR Shareholdings
24th Mar 20257:00 amRNSAppointment of Distribution Partner in Kenya
10th Mar 20257:00 amRNSAppointment of Joint Broker
5th Mar 202512:52 pmRNSDirector/PDMR Shareholding
5th Mar 20257:00 amRNSDirector/PDMR Shareholding
4th Mar 20252:13 pmRNSDirector/PDMR Shareholdings
6th Feb 20252:08 pmRNSDirector/PDMR Shareholding
5th Feb 20257:00 amRNS-RInvestor Presentation via Investor Meet Company
28th Jan 202510:36 amRNSDirector/PDMR Shareholdings
13th Jan 20257:12 amRNSTrading Update
20th Dec 20247:00 amRNSRegulatory approval for Novellus+ in Mexico
16th Dec 20247:00 amRNSAppointment of Distributor in Austria
11th Dec 20247:00 amRNSMevalone Organic Input Registration in Germany
7th Nov 20247:01 amRNSTrading Update
7th Nov 20247:00 amRNSEcovelex Approval in Italy
8th Oct 202411:24 amRNSOTCQB exchange update
23rd Sep 20247:00 amRNSHalf yearly Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.